Loss of the Y chromosome has been described in patients with hematological malignancies representing a diseaseassociated chromosome marker. 1, 2 However, several studies have shown that loss of the Y chromosome with a resulting 45,X,-Y karyotype from bone marrow (BM) and peripheral blood (PB) cells of elderly males is relatively common (c.a. 8% of males older than 60 years) and in most cases must be interpreted as a normal age-related phenomenon with no pathological consequence. 1, 3 Advances of allogeneic stem cell transplantation (SCT), such as reduced intensity conditioning or haploidentical transplant settings, have favored the use of patients and/or donors of increasing age. Therefore, the chance to find healthy donors with loss of the Y chromosome is also increased.
The objective of the present study was to evaluate the influence of the loss of the Y chromosome in a 56 years old male haploidentical donor on the outcome of SCT.
The recipient was a 33-year old female with acute myeloid leukemia (AML) in relapse after autologous SCT who underwent allogeneic SCT from a non HLA-identical family donor (NIFD, father). The conditioning regimen for the allogeneic SCT consisted in thiotepa, fludarabine, melphalan and antithymocyte globulin. The G-CSF mobilized PB graft was T-cell depleted by CD34 þ immunomagnetic selection (CliniMACS, Miltenyi Biotec) to contain 7.3 CD34 þ and 0.092 CD3 þ cells Â 10 6 /kg. The patient received immunosuppressive therapy with cyclosporine A (CsA, 3 mg/kg/day Â days À1 to þ 27) as graft-versus-host disease (GVHD) prophylaxis and high dose of intravenous steroids (from day þ 60) for the treatment of naturopathic toxicity. The patient died from sepsis on day þ 201 post-SCT.
Chimerism was quantified by fluorescent in situ hybridization (FISH) for the sex chromosomes (XY-FISH) on routine PB (Figure 1 ) and BM smears, as well as on leukocyte lineages purified using immunomagnetic technology (AutoMACS, Miltenyi Biotec): T cells (CD3 þ ), both helper (CD4 þ ) and cytotoxic (CD8 þ ), B cells (CD19 þ ) and myeloid cells (CD15 þ ). . In fact, it has been shown in Turner syndrome patients show various immunological disorders. [5] [6] [7] Moreover, monosomy X in T cells would be related to an increased spontaneous as well as death receptor-meditated apoptosis. 8 In addition, monosomy X T cells and monocytes of these patients showed a decreased sensitivity to insulin-like growth factor I (IGF-1) and growth hormone, and therefore a decreased monocyte-stimulated T lymphocyte proliferation. 9 On the other hand, studies aimed to identify specific genes responsible for the Turner syndrome phenotype suggest that many characteristic features are caused by haploinsufficiency of specific genes for which a diploid dosage would be required for their normal function. 10, 11 Although, to our knowledge, no genes have been specifically involved in the mentioned T-cell deficiency, this hypothesis could account for the immune alterations observed in these patients. Within this scenario, a number of studies have described the genes associated with the human Y chromosome and efforts to understand their biological functions are being made. 12, 13 Candidate genes to have a role in the proliferation and/or maturation of such cells would be cytokine receptors, such as the interleukin 3 receptor.
It has been postulated that an age-related increase of X,-Y cells could result in two ways, 1 it could be due to the cumulative loss of the Y chromosome from individual cells through errors of cell division, or it could arise from a single X,-Y cell and a gradual replacement of the XY cells. In the case reported here, the relative increase of XY T cells (mostly CD4 þ cells) during the post-SCT period could be either due to a reduced rate of generation/ maturation as well as to an increased rate of elimination of X,-Y T cells. In this context, it is possible that X,-Y lymphocytes showed increased sensitivity, compared to normal XY cells, to the high dose of immunosuppressive drugs, through as yet unknown mechanisms, that the patient received during the post SCT period. In any case, regardless of the ultimate cause for the loss of X,-Y T-cells (mainly CD4 þ T cells) observed after SCT in the patient reported here, it could have compromised the immune capacity of the patient, who in fact had various infectious complications and died from sepsis on day þ 201 post-SCT.
In conclusion, male donors, older than 50 years, should be studied by XY-FISH on PB samples in order to rule out the loss of the Y chromosome. If this is detected, the follow-up of the recipient patients, should pay special attention on their immune recovery, in order to gain insight into its implication in the outcome of SCT, and eventually validate or censure the use of such donors. 
